Trials / Unknown
UnknownNCT04412473
COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits
COVID-19 Respiratory Distress and Antithrombotic Drugs inSubject's Habits
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS
Conditions
Timeline
- Start date
- 2020-04-30
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2020-06-02
- Last updated
- 2021-01-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04412473. Inclusion in this directory is not an endorsement.